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Abstract: It is assumed that healthcare workers are at the highest risk to be infected by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). However, few data from healthcare workers
who do not primarily take care of patients with SARS-CoV-2 infection support this assumption. We
investigated the prevalence of immunoglobulin G (Ig G) against SARS-CoV-2 among healthcare
workers who do not primarily take care of patients with SARS-CoV-2 infection and the general
population in a well-defined geographical area. The first part of the study was conducted in May
2020 in Val Mesolcina (Southern Switzerland), a valley with ~8000 inhabitants. All healthcare
workers were invited. All participants (n = 488) of the Swiss Longitudinal Cohort Study (SWICOS), a
cohort representative of the general population, were also invited. Circulating Ig G against spike
protein subunit 1 of SARS-CoV-2 were tested in each subject. Subjects with positive Ig G were
tested again after 6 months. The condition of being a healthcare worker, rather than a part of
the general population, was tested as a predictor of seroprevalence positivity by both simple and
multiple (adjusted for age and sex) logistic regression. Eleven (2.6%) of the 423 SWICOS participants
and 46 (16%) out of 289 healthcare workers were positive for antibodies against SARS-CoV-2. The
seroprevalence OR was 7.01 (95% CI: 3.53–15.47) for healthcare workers as compared to SWICOS
participants. After adjusting for age and gender, the seroprevalence OR was 5.13 (95% CI: 2.54–10.40).
About three quarters of the subjects in the SWICOS (73%) and in healthcare (79%) group with a
previous positive serology still presented positive Ig G against the SARS-CoV-2 after 6 months. The
present seroprevalence data point out that the SARS-CoV-2 infection is seven times higher among
healthcare workers than in the general population of Val Mesolcina. Efforts to effectively protect all
the healthcare personnel are needed.
Keywords: COVID19; SARS-CoV-2; infection risk; healthcare providers; physicians
1. Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is mainly transmitted
by air droplets [1]. It is therefore assumed the healthcare workers are at the highest risk
to be infected [2]. Although this assumption was not always confirmed and a few reports
observed a rather low prevalence of seroconversion among health personnel [3,4], most
investigations reported a relevant incidence of infection among healthcare workers who
care patients affected with (COVID19) [5,6]. Limited data are available on health care
providers who do not primary take care of COVID19 patients [2]. The aim of this study was
to compare the coronavirus disease 19 prevalence of Ig G antibodies against SARS-CoV-2
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of healthcare workers, who do not primary take care of COVID19 patients, with those
of the general population in a well-defined geographical area during the first wave of
the pandemic in spring 2020. The secondary aim was to investigate the persistence of
antibodies in subjects with a positive serology.
2. Results
2.1. Study Participants
A total of 423 (87%) out of the 488 Swiss Longitudinal Cohort Study (SWICOS) par-
ticipants and 289 (84%) out of the 344 healthcare workers of Val Mesolcina volunteered
to participate. Demographics, comorbidities and relevant drug treatments of the study
participants are given in Table 1. The SWICOS participants were older and more frequently
male than healthcare workers.
Table 1. Characteristics of the healthcare workers and Swiss Longitudinal Cohort Study SWICOS
participants included in the study.
Charachteristics All HealthcareWorkers
SWICOS
Participants
n 712 289 423
Age (years), mean ± SD 50 ± 16 44 ± 15 ** 53 ± 16
Female gender, n (%) 437 (61) 202 (70) ** 235 (56)
Comorbidities, n (%)
Diabetes mellitus 17 (2.4) 4 (1.4) 13 (3.1)
COPD & or asthma 32 (4.5) 7 (2.4) 25 (5.9)
Arterial hypertension 73 (10) 15 (5.2) ** 58 (14)
Cardiovascular diseases 28 (3.9) 3 (1.0) ** 25 (5.9)
Autoimmune diseases 12 (1.7) 4 (1.4) 8 (1.9)
Cancer 15 (2.1) 3 (1.0) 12 (2.8)
No comorbidity, n (%) 571 (80) 259 (90) *** 312 (74)
Relevant drug treatment, n (%)
Immunosuppressants ˆ 41 (5.8) 7 (2.4) ** 34 (8.0)
ACE-inhibitors or sartans 48 (6.7) 11 (3.8) * 37 (8.7)
& Chronic obstructive pulmonary disease; ˆ including systemic corticosteroids. * = p < 0.05, ** = p < 0.002,
*** = p < 0.0001.
Arterial hypertension, cardiovascular diseases, and medication with immunosuppres-
sants, ACE-inhibitors or sartans were more common among SWICOS participants.
2.2. Prevalence of IgG against SARS-CoV-2 and Clinical History
Only 11 (2.6%) out of the 423 SWICOS participants were positive for Ig G against
SARS-CoV-2. This figure was relevantly higher (p < 0.0001) for healthcare workers: a
total of 46 (16%) out of 289 were positive for antibodies against SARS-CoV-2. Among
the 46 healthcare workers with anti-SARS-CoV-2 Ig G, 31 were active in long-term care
facilities for elderly, 12 in outpatient clinics and 3 in home care services (Table 2). They
were 23 paramedics, 14 nurses, 6 physicians and 3 student paramedics.
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Table 2. Demographic data, detection of SARS-CoV-2 Ig G at baseline and clinical history from January 2020 of healthcare
workers and SWICOS participants.
Variables
All Healthcare Workers SWICOS Participants
Ig G
Positive
Ig G
Negative
Ig G
Positive
Ig G
Negative
Ig G
Positive
Ig G
Negative
n 57 655 46 243 11 412
Age (years), mean ± SD 41 *** ± 15 50 ± 17 40 ± 16 44 ± 15 47 ± 6.9 53 ± 17
Gender, female, n (%) 41 (73) 398 (61) 31 (67) 171 (70) 8 (73) 227 (55)
At least one comorbidity, n (%) 9 (16) 132 (20) 7 (15) 23 (9.5) 2 (18) 109 (26)
Immunosuppressants, n (%) 4 (7.0) 37 (5.6) 3 (6.5) 4 (8.2) 1 (9.1) 33 (8.0)
ACE-inhibitors or sartans, n (%) 3 (5.3) 45 (6.9) 2 (4.3) 9 (3.7) 1 (9.1) 36 (8.7)
Clinical History, n (%)
Upper respiratory symptoms 49 *** (86) 346 (53) 43 *** (93) 126 (52) 6 (55) 220 (55)
Lower respiratory symptoms 6 (11) 31 (4.7) 6 * (13) 12 (4.9) 0 (0.0) 19 (4.6)
Anosmia 32 *** (57) 30 (4.6) 28 *** (61) 7 (2.9) 4 * (36) 23 (5.6)
Diarrhea 17 (30) 124 (19) 13 (28) 41 (17) 4 (36) 83 (20)
Fever 26 *** (46) 112 (17) 20 ** (43) 49 (20) 6 ** (55) 63 (15)
Asthenia 42 *** (74) 280 (43) 34 *** (74) 92 (38) 8 (73) 188 (46)
Muscle ache 25 *** (44) 179 (27) 18 (39) 64 (26) 7 * (63) 115 (28)
* = p < 0.05, ** = p < 0.002, *** = p < 0.0001, versus IgG negative.
Upper respiratory symptoms, anosmia, fever, asthenia, and muscle ache were more
frequently reported by the 56 subjects with antibodies against SARS-CoV-2 as compared to
the 656 subjects without. The tendency was on the average similar in healthcare workers
and in the general population.
2.3. Clinical History and Lifestyle Characteristics of Subjects with IgG against SARS-CoV-2
The prevalence of at least one comorbidity, and medications with immunosuppres-
sants, ACE-inhibitors or sartans was similar among SWICOS participants and healthcare
workers with Ig G anti-SARS-CoV-2 (Table 2). Similarly, smoking habits were not different
(p = 0.2) in SWICOS participants (previous smokers, n = 4; non-smokers, n = 7) and health-
care workers (current smokers, n = 10; previous smokers, n = 9; non-smokers, n = 27) with
Ig G anti-SARS-CoV-2. On the contrary, SWICOS participants were more frequently users
of public transports as compared with healthcare workers (4 out 11 vs 3 out 46, respectively,
p < 0.05).
The seroprevalence OR for healthcare workers as compared to SWICOS participants
was 7.01. After adjusting for age and gender, the seroprevalence OR was slightly lower
(5.13), as shown in Table 3.
Table 3. Odds ratio (ORs) of presenting Ig G against SARS-CoV-2 and corresponding 95% confidence
interval (95% CI) among healthcare workers compared with the general population (univariate and
multiple logistic regression).
Type of Model ORs 95% CI p Value
Unadjusted model 7.01 3.53–15.47 <0.001
Adjusted model * 5.13 2.54–10.40 <0.001
* Age and gender were used for the adjustment.
2.4. Follow-Up Serology of Subjects with Ig G Anti-SARS-CoV-2
All SWICOS participants (n = 11) and 39 out of 46 healthcare workers with positive Ig
G against SARS-CoV-2 at baseline participated in the follow-up examination: a total of 8
(72%) out 11 and 31 (79%) out of 39 subjects still presented Ig G against SARS-CoV-2. The
frequency was similar in the two groups (p = 0.49).
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3. Discussion
The present seroprevalence study points out that the SARS-CoV-2 infection is seven
times higher among healthcare workers than in the general population of Val Mesolcina. In
both groups, symptoms consistent with SARS-CoV-2 infection were more common among
subjects with Ig G antibodies as compared to subjects without. Moreover, antibodies persist
at 6 months in approximately three quarters of the cases (with a similar figure in both
study groups).
Healthcare workers of Val Mesolcina do not primarily take care of acute SARS-CoV-2
patients, because these patients are managed in other hospitals of Southern Switzerland.
Hence, we speculate that the contact with undiagnosed, mildly symptomatic subjects in
outpatient clinics or outbreaks in long-term care facilities might have played a significant
role in SARS-CoV-2 infection in this group of workers. The finding that the healthcare
workers with Ig G anti SARS-CoV-2 used less frequently public transports, a possible
source of SARS-CoV-2 infection [7], further supports the mentioned hypothesis.
Smokers have been considered at lower risk of SARS-CoV-2 infection, but at higher
risk of a severe disease [8]. In our rather small sample, no difference in smoking habits was
found between healthcare workers and the general population with Ig G against SARS-
CoV-2, thus precluding a major role of smoking in SARS-CoV-2 susceptibility. Furthermore,
no difference was observed between the two populations, regarding the presence of at least
one comorbidity and medications with immunosuppressants, ACE-inhibitors or sartans,
three further factors possibly associated with the risk of infection [9].
Studies conducted in hospital-based settings found an increased risk of SARS-CoV-2
infection among healthcare workers. In a survey conducted in UK and USA, healthcare
workers managing COVID19 inpatients were more frequently infected by SARS-CoV-2
(hazard ratio of 3.40, 95% CI 3.37–3.43) as compared with the general community [10]. A
study including a cohort of healthcare workers active in two USA university hospitals and
a cohort of university members not active in healthcare reported a 7.0% (95% CI 4.7–9.3)
greater absolute risk of SARS-CoV-2 infection, as documented by oropharyngeal swabs,
in the first cohort [11]. Taken together, the results of these investigations and those of our
study point out that the risk of SARS-CoV-2 infection is markedly increased among all
healthcare workers.
Using the laboratory assay applied for our study, the seroprevalence in healthcare
workers of a tertiary hospital in Germany was 1.6 % [12]. The difference with our data may
result from the very high burden of SARS-CoV-2 observed in Southern Switzerland during
the first wave pandemic [4]. Moreover, healthcare providers working in SARS-CoV-2-free
departments in Switzerland do not dress N95 masks but only surgical masks [13], which
provide a limited protection against this virus [14,15]. Therefore, insufficient personal
protective measures might have also played a role in facilitating the virus spread among
healthcare workers. Since healthcare workers face every day the consequences of this
unexpected infectious threat, often with poor resources and in stressful conditions, new
efforts should be made to support this category [16].
The rather high frequency of subjects with persistent Ig G at 6 months is likely related
to the fact that the vast majority of them had a previous history with symptoms consistent
with SARS-CoV-2 infection. However, the relevance of persisting Ig G levels is still matter
of debate [17–19].
This study has both limitations and strengths. It was performed with an Ig G assay
against the SARS-CoV-2, which is validated and reliable for population studies [20]. Re-
grettably, we did not measure Ig M or Ig A. However, the role of Ig M and Ig A in this
condition is still to be elucidated. Moreover, we did not track possible infections among
family members and other contacts. The main strength is that this study was conducted in
a well-defined geographical area.
In conclusion, this study suggests that healthcare workers who do not take care of
COVID19 inpatients are five times more at risk of SARS-CoV-2 infection than the general
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population. Efforts to more effectively protect and support all the healthcare personnel are
needed for the current coronavirus pandemic and for any possible new emergency.
4. Materials and Methods
The first part of this study was conducted between May 15 and 31, 2020 in Val Mesol-
cina, an alpine valley in Southern Switzerland with ~8′000 inhabitants. All subjects of the
Swiss Longitudinal Cohort Study, a prospective investigation involving 488 subjects repre-
sentative of the general population of the valley [21], were invited to participate the study
by mail. Moreover, healthcare workers active in long-term care facilities, outpatient clinics,
homecare or ambulance services of the valley were asked to participate through the heads
of the healthcare structures or services. Healthcare workers directly involved in the man-
agement of COVID19 inpatients were not included, because no institution responsible for
the care of this condition is present in Val Mesolcina. After written consent, the participants
filled-in a structured questionnaire. The questionnaire addressed the following issues:
(1) demographics (age and gender), (2) clinical history from January 2020, comprising
symptoms consistent with SARS-CoV-2 infection, comorbidities (diabetes mellitus, chronic
obstructive pulmonary disease or asthma, arterial hypertension, cardiovascular diseases,
autoimmune diseases, cancer), medication with immunosuppressants, ACE-inhibitors or
sartans and, finally (3) current lifestyle, including smoking habit (current smoker, previous
smoker, non-smoker) and the use of public transports (≥3 times per week). Finally, blood
was drawn to detect specific Ig G against spike protein subunit 1 of SARS-CoV-2 using
an enzyme-linked immunosorbent assay (Euroimmun Medizinische Labordiagnostika,
Lübeck, Germany) [20]. The cut-off value for positivity was >1.1 as recommended by the
manufacturer [22]. The questionnaire and the blood tests were performed in the same
period for both the groups.
In the second part of the study, performed 6 months later, blood was collected for a
new serology in subjects (both SWICOS participants and healthcare workers) found to be
positive for Ig G in the first part of the study.
Continuous data are presented as mean (±standard deviation) and were analyzed us-
ing the two-tailed t-test. Categoric data are presented as absolute number (and percentage)
and were analyzed using the Fisher test. The condition to be a healthcare worker, rather
than to be part of the general population, was tested as a predictor of seroprevalence posi-
tivity by a simple logistic regression. Anticipating a possible difference in demographics
between the healthcare worker and the general population group, the results of the logistic
regression were also adjusted for age and gender. The Ethics Committee of Nordwest-und
Zentralschweiz approved this study (EKNZ 2014-209).
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G.T., A.W.S. and F.M. All authors have read and agree to the published version of the manuscript.
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